Literature DB >> 33132073

Predicting which patients may benefit from the hybrid intracavitary+interstitial needle (IC/IS) applicator for advanced cervical cancer: A dosimetric comparison and toxicity benefit analysis.

Yesenia Gonzalez1, Fantine Giap2, Peter Klages1, Amir Owrangi2, Xun Jia1, Kevin Albuquerque3.   

Abstract

PURPOSE: The purpose of this study is to compare the predicted rate of local control and bladder and rectum toxicity rates for image-guided adaptive brachytherapy plans using a tandem and ovoid (T/O) applicator versus using a simulated hybrid intracavitary/interstitial tandem and ring applicator with needles (T/R + N) for patients with locally advanced cervical cancer (LACC). METHODS AND MATERIALS: Patients with ≥ FIGO Stage IIB locally advanced cervical cancer treated with T/O from a single institution were included. Simulated treatment plans were created with a T/R + N applicator for the best high-risk clinical target volume (CTV) coverage and minimal dose to organs at risk. Three-year local control rate was estimated using published dose-volume effect relationships. Next, the high-risk CTV EQD2 D90 of T/R + N plans were calculated, and bladder and rectum toxicity rates were estimated. Analysis was performed in subpatient groups defined based on tumor volume and ratio of maximal and minimal tumor radii (RR) that reflects tumor shape asymmetry.
RESULTS: Improvements in predicted local control rate for the T/R + N were 0.8, 4.1, 1.6, and 3.9% for groups with tumor volume <35 cc, ≥35 cc, RR < 2.0, and ≥2.0, respectively, with the latter three being statistically significant. Predicted reductions in Grade 2-4 toxicity rates of bladder and rectum were significant in all groups except bladder toxicity in tumor volume <35 cc, when T/R + N plans were normalized to the same CTV coverage as the T/O plans. Comparing unnormalized T/R + N plans and T/O plans, predicted toxicity reductions were significant in all groups except rectum toxicity in RR ≥ 2.0. Predicted reduction of toxicity rate was larger for patients with large tumor or large tumor RR, although some reductions were relatively small.
CONCLUSIONS: Cases with large tumor (volume ≥35 cc) or large tumor asymmetry (RR ≥ 2.0) would probably benefit more from the use of hybrid applicators.
Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; High-dose-rate; Hybrid applicator

Year:  2020        PMID: 33132073     DOI: 10.1016/j.brachy.2020.09.004

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

Review 1.  Evolution of Brachytherapy Applicators for the Treatment of Cervical Cancer.

Authors:  Ankur Mourya; Lalit Mohan Aggarwal; Sunil Choudhary
Journal:  J Med Phys       Date:  2021-12-31

2.  Japanese Society for Radiation Oncology Consensus Guidelines of combined intracavitary and interstitial brachytherapy for gynecological cancers.

Authors:  Naoya Murakami; Tatsuya Ohno; Takafumi Toita; Ken Ando; Noriko Ii; Hiroyuki Okamoto; Toru Kojima; Kayoko Tsujino; Koji Masui; Ken Yoshida; Hitoshi Ikushima
Journal:  J Radiat Res       Date:  2022-05-18       Impact factor: 2.724

3.  An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma.

Authors:  Naoya Murakami; Ken Ando; Masumi Murata; Kazutoshi Murata; Tatsuya Ohno; Tomomi Aoshika; Shingo Kato; Noriyuki Okonogi; Anneyuko I Saito; Joo-Young Kim; Yasuo Yoshioka; Shuhei Sekii; Kayoko Tsujino; Chairat Lowanichkiattikul; Poompis Pattaranutaporn; Yuko Kaneyasu; Tomio Nakagawa; Miho Watanabe; Takashi Uno; Rei Umezawa; Keiichi Jingu; Ayae Kanemoto; Masaru Wakatsuki; Katsuyuki Shirai; Hiroshi Igaki; Jun Itami
Journal:  J Radiat Res       Date:  2022-05-18       Impact factor: 2.724

4.  Now is it time to implement spacers in cervical cancer brachytherapy?

Authors:  Naoya Murakami; Kae Okuma; Tomoyasu Kato; Hiroshi Igaki
Journal:  J Radiat Res       Date:  2022-07-19       Impact factor: 2.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.